BridgeMD
New treatment option for Neuropathic Pain
Official title Cortical Stimulation by Direct Current for the Treatment of Chronic Pain : Pilot-study of a Stimulation Device at Home
ClinicalTrials.gov ID: NCT02346396
What this study is testing
- What it's testing
- The purpose of this study is to confirm the analgesic effect of tDCS in neuropathic chronic pain, to estimate the importance and the duration of this effect, and to improve its efficiency by the use at home. It is established that the repetition of the sessions of cortical stimulation over a week improves their analgesic efficacy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients from 18 to 80 years old, men or women, suffering pharmaco-resistant neuropathic chronic pain for more than one year; NVS \> 2 during the...
- Patients whose pharmacoresistance leads their referent doctor to consider non-pharmacological therapeutic alternatives and begin a presurgical...
- Patients having an operational Internet connection. The patient or one person of its circle of acquaintances will have to be able to connect on the...
- Patients having shown pain relief to a single- or whole-week sessions of tDCS are not excluded from potential recruitment for this study.
- Patients having a social security cover.
You likely can't join if
- History
- of addiction to drugs,
- of epilepsy.
- Présence of an intra-cranial ferromagnetic equipment or of an implanted stimulation device (e.g. stimulating, central grey pacemaker, stimulation of...
- Introduction of a new analgesic treatment for less than a month.
- Lack of a effective contraception for all the duration of the study for the patients old enough to procreate. (No limitation in the inclusion of male...
See the full eligibility criteria
- Patients from 18 to 80 years old, men or women, suffering pharmaco-resistant neuropathic chronic pain for more than one year; NVS \> 2 during the week S0) unilateral pharmacoresistant, whose analgesic treatment is...
- Patients whose pharmacoresistance leads their referent doctor to consider non-pharmacological therapeutic alternatives and begin a presurgical assessment.
- Patients having an operational Internet connection. The patient or one person of its circle of acquaintances will have to be able to connect on the Internet and to reach by this way the system of relocated stimulation...
- Patients having shown pain relief to a single- or whole-week sessions of tDCS are not excluded from potential recruitment for this study.
- Patients having a social security cover.
- Patients having given their written consent.
- History
- of addiction to drugs,
- of epilepsy.
- Présence of an intra-cranial ferromagnetic equipment or of an implanted stimulation device (e.g. stimulating, central grey pacemaker, stimulation of the basal ganglia or of the vagus nerve).
- Introduction of a new analgesic treatment for less than a month.
- Lack of a effective contraception for all the duration of the study for the patients old enough to procreate. (No limitation in the inclusion of male patients old enough to procreate).
- Patient under legal protective measure.
- Pregnant women and nursing mothers
The study team makes the final eligibility decision.
Where it's taking place
- Bron, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bron, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.